{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:15:57Z","timestamp":1794492957778,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijrobp.2019.08.007","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T11:30:10Z","timestamp":1565695810000},"page":"1086-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results"],"prefix":"10.1016","volume":"105","author":[{"given":"Anna M.E.","family":"Bruynzeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyama U.","family":"Tetar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swie S.","family":"Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.A.","family":"Haasbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke O.B.","family":"Spoelstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.M.","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Meijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein A.B.","family":"Bakker van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Fraikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reindert J.A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Lagerwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.08.007_bib1","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/cncr.30034","article-title":"Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012","volume":"122","author":"Baker","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/cncr.31190","article-title":"Travel distance and stereotactic body radiotherapy for localized prostate cancer","volume":"124","author":"Mahal","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low \u03b1\/\u03b2 ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib5","first-page":"1009","article-title":"Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib7","first-page":"e1668","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: A ten-year analysis","volume":"9","author":"Katz","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: A systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib9","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation\u00a0therapy for localized prostate cancer: An ASTRO, ASCO,\u00a0and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib10","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/S0167-8140(18)30909-5","article-title":"OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial","volume":"127","author":"Widmark","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib11","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib17","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib18","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/cncr.28594","article-title":"Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer","volume":"120","author":"Roach","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib19","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.critrevonc.2010.11.003","article-title":"Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Combined hormone therapy and radiation therapy for locally advanced prostate cancer","volume":"84","author":"Bolla","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semradonc.2018.02.002","article-title":"Magnetic resonance imaging for target delineation and daily treatment modification","volume":"28","author":"Kashani","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials","volume":"1","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2010.04.046","article-title":"Health-related quality of\u00a0life\u00a0after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer","volume":"80","author":"Morton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.semradonc.2017.02.006","article-title":"Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer","volume":"27","author":"Kishan","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.08.007_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"1","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619336405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619336405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:46:20Z","timestamp":1759743980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619336405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0360301619336405"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.007","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}